Advaxis (NASDAQ:ADXS) Lowered to “Hold” at ValuEngine

Share on StockTwits

ValuEngine lowered shares of Advaxis (NASDAQ:ADXS) from a buy rating to a hold rating in a research note released on Thursday, ValuEngine reports.

Other equities research analysts have also issued reports about the company. Zacks Investment Research upgraded Flagstar Bancorp from a hold rating to a buy rating and set a $38.00 price objective for the company in a research note on Monday, July 8th. HC Wainwright reiterated a neutral rating on shares of Aerpio Pharmaceuticals in a research note on Wednesday, June 12th.

Shares of Advaxis stock opened at $1.27 on Thursday. Advaxis has a twelve month low of $1.21 and a twelve month high of $24.60. The company has a 50-day simple moving average of $2.15.

Advaxis (NASDAQ:ADXS) last announced its quarterly earnings results on Monday, June 10th. The biotechnology company reported ($1.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($0.13). Advaxis had a negative net margin of 126.12% and a negative return on equity of 86.88%. The business had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $0.34 million. As a group, research analysts forecast that Advaxis will post -2.7 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. Two Sigma Investments LP increased its stake in Advaxis by 2,468.2% during the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after buying an additional 355,415 shares in the last quarter. BlackRock Inc. increased its stake in Advaxis by 3.1% during the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after buying an additional 43,368 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Advaxis by 5,970.3% during the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after buying an additional 553,031 shares in the last quarter. Institutional investors own 24.40% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

See Also: Trading Ex-Dividend Strategy

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report